Edition:
United Kingdom

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

73.27USD
19 Oct 2018
Change (% chg)

$-0.90 (-1.21%)
Prev Close
$74.17
Open
$74.15
Day's High
$74.79
Day's Low
$73.17
Volume
2,206,746
Avg. Vol
2,203,933
52-wk High
$89.53
52-wk Low
$64.27

Latest Key Developments (Source: Significant Developments)

Gilead Subsidiary To Launch Authorized Generics Of Epclusa And Harvoni For Treatment Of Chronic Hepatitis C
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Gilead Sciences ::GILEAD SUBSIDIARY TO LAUNCH AUTHORIZED GENERICS OF EPCLUSA® (SOFOSBUVIR/VELPATASVIR) AND HARVONI® (LEDIPASVIR/SOFOSBUVIR) FOR THE TREATMENT OF CHRONIC HEPATITIS C.GILEAD SCIENCES INC - LIST PRICE OF AUTHORIZED GENERICS TO REFLECT DISCOUNTS IN SYSTEM TODAY.GILEAD SCIENCES - AUTHORIZED GENERICS WILL LAUNCH AT LIST PRICE OF $24,000 FOR MOST COMMON COURSE OF THERAPY AND WILL BE AVAILABLE IN JANUARY 2019.GILEAD SCIENCES INC - CONTINUING TO PURSUE COLLABORATIONS AND LONG-TERM FINANCING MODELS, SUCH AS A POTENTIAL SUBSCRIPTION MODEL.  Full Article

Allogene Therapeutics Files For IPO Of Up To $100 Million
Friday, 14 Sep 2018 

Sept 14 (Reuters) - Allogene Therapeutics::ALLOGENE THERAPEUTICS INC FILES FOR IPO OF UP TO $100 MILLION – SEC FILING.SAYS IT INTENDS TO APPLY TO HAVE ITS COMMON STOCK LISTED ON NASDAQ GLOBAL SELECT MARKET UNDER THE SYMBOL "ALLO".SAYS GOLDMAN SACHS & CO. LLC, J.P. MORGAN, COWEN ARE AMONG UNDERWRITERS TO IPO.SAYS JEFFERIES IS AMONG UNDERWRITERS TO IPO.PROPOSED IPO PRICE IS AN ESTIMATE SOLELY FOR CALCULATING SEC REGISTRATION FEE.SAYS PFIZER INC HAS 24.6 PERCENT HOLDING IN CO BEFORE THE IPO - SEC FILING.SAYS GILEAD SCIENCES INC HAS 8.4 PERCENT HOLDING IN CO BEFORE IPO.  Full Article

Gilead Sciences And Precision Biosciences Collaborate to Develop Hepatitis B Therapies
Wednesday, 12 Sep 2018 

Sept 12 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES AND PRECISION BIOSCIENCES ANNOUNCE COLLABORATION TO DEVELOP THERAPIES AGAINST HEPATITIS B VIRUS USING ARCUS GENOME EDITING.GILEAD SCIENCES INC - PRECISION WILL BE PRIMARILY RESPONSIBLE FOR DEVELOPMENT, FORMULATION, AND PRECLINICAL EVALUATION OF INVESTIGATIONAL NUCLEASES.GILEAD SCIENCES INC - GILEAD WILL BE RESPONSIBLE FOR CLINICAL DEVELOPMENT AND COMMERCIALIZATION OF POTENTIAL THERAPIES.GILEAD SCIENCES INC - GILEAD WILL FULLY FUND RESEARCH AND DEVELOPMENT UNDER COLLABORATION.GILEAD SCIENCES INC - PRECISION IS ELIGIBLE TO RECEIVE MILESTONE PAYMENTS OF UP TO AN AGGREGATE OF $445 MILLION.  Full Article

Gilead & Galapagos Announce Filgotinib Meets Primary Endpoint In First Phase 3 Study In Rheumatoid Arthritis
Tuesday, 11 Sep 2018 

Sept 11 (Reuters) - Galapagos NV ::GILEAD AND GALAPAGOS ANNOUNCE FILGOTINIB MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN FIRST PHASE 3 STUDY IN RHEUMATOID ARTHRITIS.GALAPAGOS NV - BOTH FILGOTINIB DOSES ALSO ACHIEVED ALL KEY SECONDARY EFFICACY ENDPOINTS.GALAPAGOS NV - TOLERABILITY OF FILGOTINIB WAS CONSISTENT WITH PREVIOUSLY REPORTED STUDIES.GALAPAGOS - FILGOTINIB WAS GENERALLY WELL-TOLERATED IN FINCH 2 TRIAL, WITH NO NEW SAFETY SIGNALS VERSUS THOSE REPORTED IN PREVIOUS TRIALS OF FILGOTINIB.  Full Article

Express Scripts Announces New Recommendations "Tackling High Drug Prices"
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Express Scripts Holding Co ::SAYS ANNOUNCES NEW RECOMMENDATIONS "TACKLING HIGH DRUG PRICES".SAYS IN 2019, CO'S NATIONAL PREFERRED FORMULARY (NPF) TO PROVIDE ACCESS TO 3,886 MEDICATIONS.SAYS AMONG CHANGES TO NPF THAT TAKE EFFECT JAN. 1 ARE 48 NEW FORMULARY EXCLUSIONS.SAYS NEW FORMULARY EXCLUSIONS HAVE 22 DRUGS THAT HAVE LOW-COST GENERIC ALTERNATIVES.SAYS NEW FORMULARY EXCLUSIONS HAVE 12 INSTANCES OF COMPETITION WHERE DRUGS HAVE SAME ACTIVE INGREDIENT, BUT EXCLUDED DRUG HAS HIGHER NET COST.SAYS NEW FORMULARY EXCLUSIONS HAVE 11 SPECIALTY DRUGS THAT HAVE LOWER-COST BRAND OR BIOSIMILAR ALTERNATIVE WITH LOWER LIST PRICE.SAYS FOR TREATMENT OF HEPATITIS C, 2019 NPF WILL PREFER ZEPATIER AND HARVONI, EPCLUSA, AND VOSEVI IN PLACE OF MAVYRET.SAYS IN HIV CLASS, 2019 NPF WILL PREFER SYMFI AND SYMFI LO OVER ATRIPLA, WHICH WILL BE EXCLUDED.SAYS CHANGES IN 2019 NATIONAL PREFERRED FORMULARY WILL SAVE PLANS AN ESTIMATED $3.2 BILLION.SAYS ABOUT 0.2 PERCENT OF MEMBERS ENROLLED IN AN NPF PLAN WILL SEE A CHANGE IN 2019.  Full Article

Spring Bank Announces Positive Study Results From The Inarigivir Achieve Trial
Thursday, 2 Aug 2018 

Aug 2 (Reuters) - Spring Bank Pharmaceuticals Inc ::SPRING BANK ANNOUNCES POSITIVE STUDY RESULTS FROM THE INARIGIVIR ACHIEVE TRIAL.SPRING BANK PHARMACEUTICALS - EXPANSION OF PHASE 2 CLINICAL TRIAL BEING UNDERTAKEN BY GILEAD SCIENCES.SPRING BANK PHARMACEUTICALS - TWO ADDITIONAL COHORTS ADDED TO HBV CLINICAL PROGRAM FOR INARIGIVIR CO-ADMINISTERED WITH GILEAD'S TENOFOVIR ALAFENAMIDE.SPRING BANK PHARMACEUTICALS INC - INARIGIVIR CLINICAL PROGRAM ACCELERATED TO ENTER MULTIPLE GLOBAL PHASE 2B/3 TRIALS IN EARLY 2019.SPRING BANK PHARMACEUTICALS INC - CONTINUES TO EXPLORE COLLABORATIONS, INCLUDING WITH SIRNA COMPOUNDS TARGETING HBSAG.SPRING BANK PHARMACEUTICALS INC - PRIMARY ENDPOINTS, SAFETY AND ANTIVIRAL ACTIVITY, WERE ACHIEVED AT BOTH WEEK 12 (INARIGIVIR MONOTHERAPY) AND WEEK 24.SPRING BANK PHARMACEUTICALS INC - INARIGIVIR WAS WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS OBSERVED.SPRING BANK PHARMA - ANTICIPATES INARIGIVIR WILL BE INCLUDED IN "TRIPLE COMBINATION" CLINICAL TRIAL WITH SIRNA COMPOUND/DIFFERENT MECHANISM IN H1 2019.  Full Article

Gilead Sciences Announces Third Quarter 2018 Dividend
Wednesday, 25 Jul 2018 

July 25 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES INC - DECLARED A CASH DIVIDEND OF $0.57 PER SHARE OF COMMON STOCK FOR Q3 OF 2018.  Full Article

Gilead Sciences Inc QTRLY Diluted EPS Of $1.39 Per Share
Wednesday, 25 Jul 2018 

Gilead Sciences Inc ::GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS.REVISED FULL YEAR 2018 GUIDANCE FOR NON-GAAP EFFECTIVE TAX RATE -.QTRLY DILUTED EPS OF $1.39 PER SHARE.QTRLY NON-GAAP DILUTED EPS OF $1.91 PER SHARE.REVISED FULL YEAR 2018 GUIDANCE FOR NON-GAAP EFFECTIVE TAX RATE.NON-GAAP DILUTED EPS OF $1.91 PER SHARE IN QUARTER.Q2 EARNINGS PER SHARE VIEW $1.56, REVENUE VIEW $5.21 BILLION -- THOMSON REUTERS I/B/E/S.QTRLY HARVONI SALES $331 MILLION VERSUS $1,382 MILLION.SEES NET PRODUCT SALES $20,000 MILLION - $21,000 MILLION IN FY.SEES 2018 NET PRODUCT SALES $20 BILLION - $21 BILLION.QTRLY TOTAL REVENUE $5,648 MILLION VERSUS $7,141 MILLION.Q2 EARNINGS PER SHARE VIEW $1.56, REVENUE VIEW $5.21 BILLION -- THOMSON REUTERS I/B/E/S.FY2018 REVENUE VIEW $20.81 BILLION -- THOMSON REUTERS I/B/E/S.  Full Article

European Commission Grants Marketing Authorization For Gilead’s Biktarvy For Treatment Of Hiv-1 Infection
Monday, 25 Jun 2018 

June 25 (Reuters) - Gilead Sciences Inc ::EUROPEAN COMMISSION GRANTS MARKETING AUTHORIZATION FOR GILEAD’S BIKTARVY® (BICTEGRAVIR, EMTRICITABINE, TENOFOVIR ALAFENAMIDE) FOR THE TREATMENT OF HIV-1 INFECTION.GILEAD SCIENCES - EUROPEAN COMMISSION GRANTED MARKETING AUTHORIZATION FOR BIKTARVY (BICTEGRAVIR 50MG/EMTRICITABINE 200 MG/TENOFOVIR ALAFENAMIDE 25 MG).  Full Article

Gilead, Galapagos Announce Results With Filgotinib In Phase 2 EQUATOR Study In Psoriatic Arthritis
Wednesday, 30 May 2018 

May 30 (Reuters) - Galapagos NV : :GILEAD AND GALAPAGOS ANNOUNCE RESULTS WITH FILGOTINIB IN THE PHASE 2 EQUATOR STUDY IN PSORIATIC ARTHRITIS AND PROGRESSION INTO PHASE 3 FOR THE SELECTION STUDY IN ULCERATIVE COLITIS.GALAPAGOS NV - EQUATOR ACHIEVES PRIMARY ENDPOINT OF ACR20 RESPONSE AT WEEK 16.GALAPAGOS - CO TO GET $15 MILLION PAYMENT FROM GILEAD FOR PROGRESSION INTO PHASE 3 OF PHASE 2B/3 SELECTION STUDY OF FILGOTINIB IN ULCERATIVE COLITIS.GALAPAGOS NV - FILGOTINIB WAS GENERALLY WELL-TOLERATED IN EQUATOR TRIAL, WITH NO NEW SAFETY SIGNALS OBSERVED.GALAPAGOS NV - THERE WAS ONE SERIOUS INFECTION IN FILGOTINIB GROUP, A PATIENT WHO EXPERIENCED PNEUMONIA WITH A FATAL OUTCOME IN TRIAL.GALAPAGOS NV - IN TRIAL ONE OTHER PATIENT RECEIVING FILGOTINIB DEVELOPED HERPES ZOSTER.GALAPAGOS NV - THERE WERE NO CASES OF OPPORTUNISTIC INFECTION, TUBERCULOSIS, THROMBOEMBOLISM, OR MALIGNANCY IN TRIAL.  Full Article

REFILE-Drop in Australia HIV sparks call for greater drug roll-out

LONDON, Oct 17 (Thomson Reuters Foundation) - HIV transmission rates among gay and bisexual men fell by almost a third in the Australian state of New South Wales following the wide-scale introduction of a daily anti-HIV drug, sparking calls for other health authorities to follow suit.